Press Releases
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
ILiAD Biotechnologies Announces Presentation at the World Vaccine Congress
Cecelia Health Clinicians Report Priority for Participants Has Shifted to Disease Management in Post-Pandemic Period
Cecelia Health delivers remarkable 3.7x ROI for health plans
Bigfoot Biomedical Real-World Data Demonstrate the Potential for Rapid and Durable Improvement in Glycemic Control for People with Insulin-requiring Diabetes Using the Bigfoot Unity® System
Bigfoot Biomedical Acquires Reinforcement Learning Algorithm for Insulin Titration Developed at McGill University
Bigfoot Biomedical Named to Fast Company’s “World’s Most Innovative Companies” List
Bigfoot Biomedical Receives FDA Clearance for Bigfoot Unity® Android App for People Living with Insulin-Requiring Diabetes
Bigfoot Biomedical Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery Technologies
Capillary Biomedical Tandem Diabetes Care Acquires Capillary Biomedical
Bigfoot Biomedical Diabetes tech is off to a hot start in 2022 – Drug Delivery Business
Cecelia Health Joslin Diabetes Center Collaborates with Cecelia Health to Improve Continuous Glucose Monitor (CGM) Adoption Among Older Adults with Diabetes
ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform
Capillary Biomedical “Feasibility of an Investigational Extended Wear Infusion Set for Insulin Pump Therapy (IPT) in People with Type 1 Diabetes Mellitus.” presented at ADA’s 81st Scientific Sessions
Bigfoot Biomedical® Acquires Assets of Common Sensing Bigfoot Biomedical announced today that it has acquired the intellectual property assets of Common Sensing, a Cambridge, MA-based company that develops and manufactures data-driven hardware and software solutions for people using injectable medicine, including Gocap.
Illuminare Biotechnologies Novel Nerve Visualization Investigational Fluorophore Receives FDA IND Approval for First-In-Human Trial
Bigfoot Biomedical® Secures up to $57 Million in Combined Debt and Equity Financing from Madryn Asset Management
LifeScan Partners with Cecelia Health to Provide Personalized Diabetes Health Management Coaching for OneTouch® Consumers
Coaching allows OneTouch consumers to have meaningful one-on-one interactions with clinicians to drive positive behavior change for people with diabetes and related conditions to live their best lives
Capillary Biomedical Receives $1.5 Million from Helmsley Charitable Trust for Clinical Trials of New Insulin Infusion Technology
Funding to fuel testing of extended-wear SteadiFlow technology designed to reduce infusion site failures and improve quality of life for people with diabetes
EY Announces David Weingard of Cecelia Health as an Entrepreneur Of The Year® 2020 New York Award Finalist.
Bigfoot Biomedical Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes
Bigfoot Biomedical® Closes Series C Financing with $55 Million as Company Readies for FDA Submission of Bigfoot Unity. Funding to Support its Breakthrough Therapy and Telemedicine Solutions for People Living with Insulin-Requiring Type 1 and Type 2 Diabetes
Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions
Intranasal Glucagon Could be the First Needle-Free Rescue Treatment
for Severe Hypoglycemia.
ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1
ILiAD Biotechnologies Announces Presentation of Positive Phase 2b Data for Next Generation Pertussis Vaccine at World Vaccine Congress.
Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes.
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes.
Trividia Health and Mellitus Health Partner to Develop Diabetes Care Products and Services for Pharmacies.
Mellitus Health and Glooko Announce Insulin-Dosing Software Integration Agreement.
ILiAD Biotechnologies Announces Publication of BPZE1 Adult Phase 2b Clinical Results in The Lancet
ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine
ILiAD Biotechnologies Announces Presentation of Additional Positive Data for its Next Generation Pertussis Vaccine at the 13th International Bordetella Symposium
Cecelia Health Improving outcomes for children and adolescents living with Type 1 diabetes is the goal of a collaboration between UBMD Pediatrics and Cecelia Health
Cecelia Health LifeScan and Cecelia Health Sign Expanded Multi-Year Partnership to Offer Live Diabetes Telehealth Support in Combination with OneTouch® Solutions Integrated Holistic Health Tools and OneTouch® Blood Glucose Monitoring
Capillary Biomedical Reports Best-in-Class Clinical Feasibility Results for its SteadiFlow Seven-Day-Wear Infusion Set Technology at ADA Scientific Sessions
Bigfoot Biomedical®Receives FDA Clearance for Bigfoot Unity™ Diabetes Management System, Featuring First-of-its-Kind Smart Pen Caps for Insulin Pens used to Treat Type 1 and Type 2 Diabetes
Cecelia Health Study Finds Mental Health Has Been A Bigger Concern for People Living with Diabetes than Diabetes Itself During Covid-19
Validation Institute certifies that Cecelia Health diabetes program is proven to reduce A1C
Level 2 outcomes certification validates impressive results of Cecelia Health’s diabetes management program.
Cecelia Health Diabetes Management Program Receives Association of Diabetes Care & Education Specialists (ADCES) Accreditation
Diabetes Education Accreditation Program (DEAP) certification underscores Cecelia Health’s commitment to providing superior care management programs to individuals living with diabetes.
Cecelia Health closes $13 million Series B, Rittenhouse’s Saul Richter and Endo Investors’ Eric Edidin to join board of directors, number of members now exceeds 150,000.
Helmsley Awards $5 Million to Evaluate Virtual Diabetes Specialty Clinic Model.